Do hormone treatments for prostate cancer cause anxiety and depression?

Christopher F. Sharpley, David R H Christie, Vicki Bitsika

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

Background: To investigate the relationship between hormone therapy (HT) and incidence of anxiety and depression among prostate cancer patients (PCa). Methods: 526 PCa patients completed a survey about their cancer status, treatment received, anxiety, and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis. Results: Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT. Conclusion: Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects seem to decrease after completion of HT.

Original languageEnglish
Pages (from-to)523-530
Number of pages8
JournalInternational Journal of Clinical Oncology
Volume19
Issue number3
Early online date1 Jun 2013
DOIs
Publication statusPublished - 2014

Fingerprint

Prostatic Neoplasms
Anxiety
Hormones
Depression
Therapeutics
Equipment and Supplies

Cite this

Sharpley, Christopher F. ; Christie, David R H ; Bitsika, Vicki. / Do hormone treatments for prostate cancer cause anxiety and depression?. In: International Journal of Clinical Oncology. 2014 ; Vol. 19, No. 3. pp. 523-530.
@article{8552bf5cbb374d6081e4676a9f206b5a,
title = "Do hormone treatments for prostate cancer cause anxiety and depression?",
abstract = "Background: To investigate the relationship between hormone therapy (HT) and incidence of anxiety and depression among prostate cancer patients (PCa). Methods: 526 PCa patients completed a survey about their cancer status, treatment received, anxiety, and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis. Results: Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT. Conclusion: Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects seem to decrease after completion of HT.",
author = "Sharpley, {Christopher F.} and Christie, {David R H} and Vicki Bitsika",
year = "2014",
doi = "10.1007/s10147-013-0569-y",
language = "English",
volume = "19",
pages = "523--530",
journal = "Journal of Japan Society for Cancer Therapy",
issn = "1341-9625",
publisher = "Springer",
number = "3",

}

Do hormone treatments for prostate cancer cause anxiety and depression? / Sharpley, Christopher F.; Christie, David R H; Bitsika, Vicki.

In: International Journal of Clinical Oncology, Vol. 19, No. 3, 2014, p. 523-530.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Do hormone treatments for prostate cancer cause anxiety and depression?

AU - Sharpley, Christopher F.

AU - Christie, David R H

AU - Bitsika, Vicki

PY - 2014

Y1 - 2014

N2 - Background: To investigate the relationship between hormone therapy (HT) and incidence of anxiety and depression among prostate cancer patients (PCa). Methods: 526 PCa patients completed a survey about their cancer status, treatment received, anxiety, and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis. Results: Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT. Conclusion: Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects seem to decrease after completion of HT.

AB - Background: To investigate the relationship between hormone therapy (HT) and incidence of anxiety and depression among prostate cancer patients (PCa). Methods: 526 PCa patients completed a survey about their cancer status, treatment received, anxiety, and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis. Results: Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT. Conclusion: Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects seem to decrease after completion of HT.

UR - http://www.scopus.com/inward/record.url?scp=84903276700&partnerID=8YFLogxK

U2 - 10.1007/s10147-013-0569-y

DO - 10.1007/s10147-013-0569-y

M3 - Article

VL - 19

SP - 523

EP - 530

JO - Journal of Japan Society for Cancer Therapy

JF - Journal of Japan Society for Cancer Therapy

SN - 1341-9625

IS - 3

ER -